Vertex Pharmaceuticals Incorporated (VRTX) Earnings Call Transcripts

Vertex Pharmaceuticals Incorporated's Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, Vertex Pharmaceuticals reported total revenue of $3.3 billion, reflecting a 12% year-over-year increase, driven by strong performance in its cystic fibrosis (CF) portfolio and new product contributions. Non-GAAP earnings per share (EPS) of $4.73 represented a 5% growth compared to the prior year. Management raised full-year revenue guidance to a range of $13.1 billion to $13.2 billion, indicating confidence in continued growth from both CF and emerging product lines, including CASGEVY and JOURNAVX.

Reported metrics

Guidance from management

Management raised full-year 2026 revenue guidance to $13.1 billion to $13.2 billion, reflecting strong performance across its franchises and continued growth expectations from both CF and new product lines.

What management said

Sure thing. Cory, I think you're asking about AMPLITUDE. So the core study that's now in Phase III in patients with 2 APOL1 alleles, moderate-to-heavy proteinuria and depressed GFR. We were really pleased and remain very pleased that the agency has provided and we have an agreement with the agency for a potential accelerated approval based on the primary endpoint at the time of the IA, which is 1 year GFR. So that's ...

Yes, Evan, thanks. As you pointed out, so far in the first half of the year, CASGEVY and JOURNAVX combined delivered about $200 million in revenue. So we're well on our way to achieving our target of $500 million-plus in that first half. CASGEVY has been a bigger contributor than JOURNAVX, but I'm not willing to give further color on the balance of the year other than to say we're very confident in getting to that $5...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape for Pove in IgAN, particularly in light of recent data from competitors. There were also questions about the sustainability of JOURNAVX's prescription growth amidst payer dynamics and formulary access challenges.

Main topics on the call

• Strong Revenue Growth — Vertex achieved total revenue of $3.3 billion in Q2 2026, a 12% increase year-over-year, with CF revenue growing 11%. Management stated, "Second quarter total revenue grew 12% year-on-year, driven by the strength of our ...
• CASGEVY Performance — CASGEVY generated $76 million in revenue, marking a 150% year-over-year growth. Management highlighted that "the strength of the CASGEVY franchise continues to build," indicating robust market adoption.
• JOURNAVX Growth — JOURNAVX revenue reached $50 million, reflecting a 70% sequential growth. Management noted, "We are extremely pleased with the prescription growth we continue to build, which is ahead of our forecast for 2026."
• Acquisition of Crinetics Pharmaceuticals — Vertex announced a definitive agreement to acquire Crinetics Pharmaceuticals, which is expected to enhance its pipeline and revenue growth. Management stated, "We believe the 2 lead assets, PALSONIFY and Atumelnant, toge...

Read the full Vertex Pharmaceuticals Incorporated transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 80 Vertex Pharmaceuticals Incorporated earnings call transcripts on record, spanning January 13, 2020 to August 3, 2026. Based on this history, Vertex Pharmaceuticals Incorporated reports quarterly. The most recent call on file is dated August 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

VRTX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

80

First call

January 13, 2020

Most recent

August 3, 2026

Reporting cadence

quarterly